Novavax is a biotechnology company focused on developing vaccines and employs roughly 851 people worldwide. Staffing data show 21 hires against 122 departures, resulting in a modest decrease in overall headcount. The figures illustrate a period of recalibrated workforce levels while the organization maintains its research, manufacturing, and corporate operations.
Engineering is the largest department with 217 employees, highlighting the company’s emphasis on research, development, and manufacturing technology. Business Management (103), Operations (98), and Finance & Administration (76) support day-to-day corporate execution, while Sales & Support accounts for 69 employees. Healthcare specialists, Risk, Safety & Compliance, Quality, and Marketing & Product collectively add just over 180 employees, and 107 team members fall into the Other category. The distribution reflects a blend of scientific expertise and the infrastructure required to bring vaccines to market.
Novavax maintains a strong Mid-Atlantic presence. Washington, DC hosts the largest cluster with 139 employees, and nearby Gaithersburg and Rockville, Maryland add 98 and 52 employees, respectively. Additional Maryland hubs such as Frederick, Germantown, and Baltimore contribute further headcount, while New York, Philadelphia, and Chicago provide smaller urban footprints. A sizable group of 462 employees is classified under Other, indicating remote or smaller satellite sites spread across the United States.